Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€12.20

€12.20

0.830%
0.1
0.830%
-
 
10.11.25 / Frankfurt WKN: A1J2YC / Name: ALS / Stock / Professional & Commercial Services / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

ALS Ltd Stock

The ALS Ltd stock is trending slightly upwards today, with an increase of €0.10 (0.830%) compared to yesterday's price.

Pros and Cons of ALS Ltd in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of ALS Ltd vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
ALS Ltd 0.830% -0.820% -0.820% 34.444% 35.196% 65.753% 105.085%
Seek Ltd -0.680% -5.229% -7.643% -5.229% 6.618% 11.538% -1.361%
Downer EDI Ltd 0.940% -0.467% 2.899% 23.837% 36.538% 39.216% 36.538%
Insperity Inc. 0.710% -24.742% -25.128% -60.272% -59.724% -73.929% -62.323%

News

Electromed Posts 17% Gain in Fiscal Q4
Electromed Posts 17% Gain in Fiscal Q4

Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s

Clene Posts 70% Revenue Drop in Q2
Clene Posts 70% Revenue Drop in Q2

Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important

Brainstorm Posts 43% EPS Gain in Q2
Brainstorm Posts 43% EPS Gain in Q2

Brainstorm Cell Therapeutics (OTC:BCLI), a biotechnology developer focused on neurodegenerative diseases, released its second quarter 2025 results on August 14, 2025. The headline news was a GAAP